On the evening of January 1, New Journey Health Technology Group (002219) announced that according to the "Public Announcement of Proposed Selected Results for Centralized Bulk Procurement of Chinese Patent Medicine Alliance" issued by the National Chinese Patent Medicine Joint Procurement Office on December 30, 2024, the company's wholly-owned subsidiary, Duyiwei Pharmaceutical, is proposed to be selected for the centralized bulk procurement of the Chinese Patent Medicine Procurement Alliance for its Duyiwei series products.
新里程：子公司产品拟中选全国中成药采购联盟集采
New Journey Health Technology Group: Subsidiary products intend to be selected for the national Chinese Patent Medicine procurement alliance.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated